Drugs / L-TIL
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07330037 | Dec 2025 → Dec 2026 expected | non-small cell lung carcinoma | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | L-TIL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07330037 ↗ |
| Modality | Cell therapy | “Autologous peripheral blood TILs will be infused 4 times” NCT07330037 ↗ |